Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5177265
Max Phase: Preclinical
Molecular Formula: C17H14N2O4
Molecular Weight: 310.31
Associated Items:
ID: ALA5177265
Max Phase: Preclinical
Molecular Formula: C17H14N2O4
Molecular Weight: 310.31
Associated Items:
Canonical SMILES: CC(=O)Nc1ccc(C(=O)/C=C/c2cccc([N+](=O)[O-])c2)cc1
Standard InChI: InChI=1S/C17H14N2O4/c1-12(20)18-15-8-6-14(7-9-15)17(21)10-5-13-3-2-4-16(11-13)19(22)23/h2-11H,1H3,(H,18,20)/b10-5+
Standard InChI Key: AGAPVUAAUIDWSP-BJMVGYQFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 310.31 | Molecular Weight (Monoisotopic): 310.0954 | AlogP: 3.45 | #Rotatable Bonds: 5 |
Polar Surface Area: 89.31 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.80 | CX Basic pKa: | CX LogP: 3.07 | CX LogD: 3.07 |
Aromatic Rings: 2 | Heavy Atoms: 23 | QED Weighted: 0.40 | Np Likeness Score: -1.14 |
1. Chitre S, Ray AM, Stevens M, Doud EH, Liechty H, Washburn A, Tepper K, Sivinski J, O'Hagan HM, Georgiadis MM, Chapman E, Johnson SM.. (2022) Bis-aryl-α,β-unsaturated ketone (ABK) chaperonin inhibitors exhibit selective cytotoxicity to colorectal cancer cells that correlates with levels of aberrant HSP60 in the cytosol., 75 [PMID:36356534] [10.1016/j.bmc.2022.117072] |
Source(1):